Secondary endpoints
DM, death, TTP, regional failure, prostate cancer
TTP, PROSTATE CANCER, METASTASIS

1. Compare patient-reported GI symptoms using the EPIC questionnaire at the end of RT and 3, 6, 12, and 60 months from end of treatment.2. Compare patient-reported GU symptoms using the EPIC questionnaire at the end of RT and 3, 6, 12, and 60 months from end of treatment.3. Compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (PCSM).4. Compare freedom from biochemical failure (FFBF) and TTP rates with an alternate PSA ≥ PSA nadir + 2 ng/mL definition of BF.5. Compare local failure, regional failure, salvage therapy (